Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/21504
Title: Bone morphogenetic protein signaling in breast cancer progression.
Austin Authors: Chi, Lap Hing;Burrows, Allan D;Anderson, Robin L 
Affiliation: Metastasis Research Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
School of Cancer Medicine, La Trobe University, Bundoora, Australia
Department of Clinical Pathology, The University of Melbourne, Parkville, Victoria, Australia
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia
Issue Date: 5-Jul-2019
metadata.dc.date: 2019-04
Publication information: Growth factors 2019: 37(1-2): 12-28
Abstract: Breast cancer is the most prevalent type of cancer amongst women worldwide. The mortality rate for patients with early-stage breast cancer has been decreasing, however, the 5-year survival rate for patients with metastatic disease remains poor, currently at 27%. Here, we have reviewed the current understanding of the role of bone morphogenetic protein (BMP) signaling in breast cancer progression, and have highlighted the discordant results that are reported in different studies. We propose that some of these contradictory outcomes may result from signaling through either the canonical or non-canonical pathways in different cell lines and tumors, or from different tumor-stromal interactions that occur in vivo.
URI: http://ahro.austin.org.au/austinjspui/handle/1/21504
DOI: 10.1080/08977194.2019.1626378
ORCID: 0000-0003-0983-3474
0000-0003-0595-1414
0000-0002-6841-7422
PubMed URL: 31272247
Type: Journal Article
Subjects: Breast cancer
SMAD4
bone morphogenetic proteins
signaling
Appears in Collections:Journal articles

Show full item record

Page view(s)

4
checked on Nov 29, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.